HYPERION DEFI, INC. Selling, General and Administrative Expense
HYPERION DEFI, INC. (HYPD) reported Selling, General and Administrative Expense of $3.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- HYPERION DEFI, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $3.92M, a 48.97% decline year-over-year.
- HYPERION DEFI, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $4.49M, a 89.42% increase year-over-year.
- HYPERION DEFI, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $4.53M, a 41.23% increase year-over-year.
- HYPERION DEFI, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $2.59M, a 30.44% decline year-over-year.
- HYPERION DEFI, INC. selling, general and administrative expense for fiscal 2025 was $17.18M, a 19.83% increase from fiscal 2024.
- HYPERION DEFI, INC. selling, general and administrative expense for fiscal 2024 was $14.33M, a 15.42% increase from fiscal 2023.
- HYPERION DEFI, INC. selling, general and administrative expense for fiscal 2023 was $12.42M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.92M 10-Q · filed 2026-08-13 | $8.41M 10-Q · filed 2026-08-13 | $12.94M derived: sum of 3 quarters · filed 2026-08-13 | $15.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.49M 10-Q · filed 2026-05-15 | $9.02M derived: sum of 2 quarters · filed 2026-05-15 | $11.62M derived: sum of 3 quarters · filed 2026-05-15 | $19.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.12M derived: sum of 2 quarters · filed 2026-03-30 | $14.80M derived: sum of 3 quarters · filed 2026-08-13 | $17.18M 10-K · filed 2026-03-30 |
| 2025-09-30 | $2.59M 10-Q · filed 2025-11-14 | $10.27M derived: sum of 2 quarters · filed 2026-08-13 | $12.65M 10-Q · filed 2025-11-14 | $15.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $7.68M 10-Q · filed 2026-08-13 | $10.05M 10-Q · filed 2026-08-13 | $13.26M derived: sum of 3 quarters · filed 2026-08-13 | $16.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.37M 10-Q · filed 2026-05-15 | $5.58M derived: sum of 2 quarters · filed 2026-05-15 | $9.31M derived: sum of 3 quarters · filed 2026-05-15 | $13.07M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.94M derived: sum of 2 quarters · filed 2026-03-30 | $10.70M derived: sum of 3 quarters · filed 2026-03-30 | $14.33M 10-K · filed 2026-03-30 |
| 2024-09-30 | $3.73M 10-Q · filed 2025-11-14 | $7.49M derived: sum of 2 quarters · filed 2025-11-14 | $11.13M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $3.76M 10-Q · filed 2025-08-13 | $7.40M 10-Q · filed 2025-08-13 | ||
| 2023-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $6.33M derived: sum of 2 quarters · filed 2025-04-15 | $12.42M 10-K · filed 2025-04-15 | |
| 2023-09-30 | $2.93M 10-Q · filed 2024-11-12 | $9.02M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |